華體科技(603679.SH):董事會決定不向下修正轉股價格
格隆匯 10 月 25日丨華體科技(603679.SH)公佈,根據公司《可轉債募集説明書》約定,在此次發行的可轉換公司債券存續期間,當公司A股股票在任意連續30個交易日中至少有15個交易日的收盤價低於當期轉股價格的85%時,公司董事會有權提出轉股價格向下修正方案並提交公司股東大會審議表決。公司現行轉股價格為33.99元,目前公司股價已觸及《可轉債募集説明書》里約定的向下修正條款。
鑑於二級市場股價受諸多因素影響,公司可轉債於2020年10月9日剛進入轉股期,目前離債券存續結束期還有很長時間,為充分兼顧債券持有人及公司中小投資者的利益,着眼公司長期發展,董事會決定本次不向下修正轉股價格。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.